Insider trades › Orbimed Advisors LLC
Orbimed Advisors LLC
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing Nov 12, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list Orbimed Advisors LLC's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks Orbimed Advisors LLC bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as Orbimed Advisors LLC?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| WWB Windward Bio Group AG | Director, 10% owner | Nov 12, 2026 |
| ETRA Electra Therapeutics, Inc. | Director, 10% owner | Nov 10, 2026 |
| ASPE Aspen Neuroscience, Inc. | Director, 10% owner | Nov 4, 2026 |
| BRVE Braveheart Bio, Inc. | Director, 10% owner | Aug 5, 2026 |
| SCTX Scribe Therapeutics Inc. | Director | Jul 29, 2026 |
| YARW Yarrow Bioscience, Inc. | Director | Jul 29, 2026 |
| SION Sionna Therapeutics, Inc. | Director | Jul 2, 2026 |
| ELVN Enliven Therapeutics, Inc. | 10% owner | Jun 24, 2026 |
| STTK Shattuck Labs, Inc. | Director | Jun 15, 2026 |
| ACET Adicet Bio, Inc. | 10% owner | Oct 10, 2025 |
| PMVP PMV Pharmaceuticals, Inc. | 10% owner | Sep 12, 2025 |
| TSBX Turnstone Biologics Corp. | Director | Aug 12, 2025 |
| IKNA ImageneBio, Inc. | Director | Jul 30, 2025 |
| CRVS Corvus Pharmaceuticals, Inc. | Director, 10% owner | Jul 1, 2025 |
| PASG Passage Bio, Inc. | 10% owner | Jun 26, 2025 |
| NPCE Neuropace, Inc. | 10% owner | May 16, 2025 |
| IRON Disc Medicine, Inc. | Director | Mar 26, 2025 |
| UPB Upstream Bio, Inc. | Director, 10% owner | Oct 17, 2024 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 2,000 | $8.45 | $16.9K | +10.0% | Form 4 ↗ |
| Nov 10, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 20,700 | $8.45 | $174.9K | +10.0% | Form 4 ↗ |
| Nov 9, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 4,000 | $8.24 | $33.0K | +7.3% | Form 4 ↗ |
| Nov 9, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 16,000 | $8.24 | $131.8K | +7.3% | Form 4 ↗ |
| Nov 6, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 39,600 | $7.85 | $310.9K | +10.7% | Form 4 ↗ |
| Nov 6, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 9,816 | $7.85 | $77.1K | +10.7% | Form 4 ↗ |
| Nov 5, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 125,200 | $7.31 | $915.2K | +17.4% | Form 4 ↗ |
| Nov 5, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 30,891 | $7.31 | $225.8K | +17.4% | Form 4 ↗ |
| Nov 4, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 37,100 | $7.78 | $288.6K | +12.5% | Form 4 ↗ |
| Nov 4, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 20,000 | $7.07 | $141.4K | +12.5% | Form 4 ↗ |
| Nov 4, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 9,267 | $7.78 | $72.1K | +12.5% | Form 4 ↗ |
| Nov 4, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 5,000 | $7.07 | $35.4K | +12.5% | Form 4 ↗ |
| Nov 3, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 24,400 | $7.88 | $192.3K | +9.5% | Form 4 ↗ |
| Nov 3, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 24,313 | $7.84 | $190.6K | +9.5% | Form 4 ↗ |
| Nov 3, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 97,800 | $7.84 | $766.8K | +9.5% | Form 4 ↗ |
| Nov 3, 2026 | ETRA Electra Therapeutics, Inc. | Buy | 98,600 | $7.88 | $777.0K | +9.5% | Form 4 ↗ |
| Nov 2, 2026 | ASPE Aspen Neuroscience, Inc. | Buy | 1.00M | $15.00 | $15.0M | -3.8% | Form 4 ↗ |
| Jul 27, 2026 | SCTX Scribe Therapeutics Inc. | Buy | 1.00M | $15.00 | $15.0M | -15.8% | Form 4 ↗ |
| Jun 30, 2026 | SION Sionna Therapeutics, Inc. | Sale | 115,844 | $45.50 | $5.3M | -93.4% | Form 4 ↗ |
| Jun 22, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 24,846 | $45.38 | $1.1M | +4.8% | Form 4 ↗ |
| Jun 22, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 1,477 | $45.00 | $66.5K | +4.8% | Form 4 ↗ |
| Jun 22, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 787,024 | $45.38 | $35.7M | +4.8% | Form 4 ↗ |
| Jun 22, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 46,776 | $45.00 | $2.1M | +4.8% | Form 4 ↗ |
| Jun 15, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 9,086 | $45.02 | $409.1K | +15.3% | Form 4 ↗ |
| Jun 15, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 272,322 | $45.02 | $12.3M | +15.3% | Form 4 ↗ |
| May 27, 2026 | SION Sionna Therapeutics, Inc. | Sale | 101 | $44.49 | $4,493 | -92.9% | Form 4 ↗ |
| May 11, 2026 | SION Sionna Therapeutics, Inc. | Sale | 184,639 | $46.22 | $8.5M | -94.8% | Form 4 ↗ |
| May 8, 2026 | SION Sionna Therapeutics, Inc. | Sale | 59,767 | $44.58 | $2.7M | -94.7% | Form 4 ↗ |
| May 7, 2026 | SION Sionna Therapeutics, Inc. | Sale | 48,546 | $44.61 | $2.2M | -95.4% | Form 4 ↗ |
| Apr 18, 2026 | SION Sionna Therapeutics, Inc. | Sale | 2,948 | $44.52 | $131.2K | -98.6% | Form 4 ↗ |
| Apr 17, 2026 | SION Sionna Therapeutics, Inc. | Sale | 52,397 | $44.68 | $2.3M | -98.6% | Form 4 ↗ |
| Apr 16, 2026 | SION Sionna Therapeutics, Inc. | Sale | 226,906 | $45.34 | $10.3M | -100.2% | Form 4 ↗ |
| Apr 15, 2026 | SION Sionna Therapeutics, Inc. | Sale | 235,863 | $44.64 | $10.5M | -100.4% | Form 4 ↗ |
| Apr 14, 2026 | SION Sionna Therapeutics, Inc. | Sale | 47,814 | $44.51 | $2.1M | -100.9% | Form 4 ↗ |
| Nov 26, 2025 | SION Sionna Therapeutics, Inc. | Sale | 1,600 | $44.49 | $71.2K | -103.4% | Form 4 ↗ |
| Nov 25, 2025 | SION Sionna Therapeutics, Inc. | Sale | 11,890 | $44.60 | $530.3K | -104.2% | Form 4 ↗ |
| Nov 24, 2025 | SION Sionna Therapeutics, Inc. | Sale | 94,583 | $44.54 | $4.2M | -105.3% | Form 4 ↗ |
| Oct 8, 2025 | ACET Adicet Bio, Inc. | Buy | 1.50M | $1.00 | $1.5M | -93.4% | Form 4 ↗ |
| Oct 8, 2025 | ACET Adicet Bio, Inc. | Buy | 3.50M | $1.00 | $3.5M | -93.4% | Form 4 ↗ |
| Sep 10, 2025 | PMVP PMV Pharmaceuticals, Inc. | Sale | 500,000 | $1.80 | $900.0K | -15.7% | Form 4 ↗ |
| Jun 27, 2025 | CRVS Corvus Pharmaceuticals, Inc. | Sale | 1.18M | $4.16 | $4.9M | +150.8% | Form 4 ↗ |
| Jun 26, 2025 | PASG Passage Bio, Inc. | Sale | 213,257 | $0.33 | $70.4K | -58.9% | Form 4 ↗ |
| Jun 25, 2025 | PASG Passage Bio, Inc. | Sale | 138,800 | $0.33 | $45.8K | -59.1% | Form 4 ↗ |
| Jun 24, 2025 | PASG Passage Bio, Inc. | Sale | 231,600 | $0.35 | $81.1K | -63.9% | Form 4 ↗ |
| May 14, 2025 | NPCE Neuropace, Inc. | Sale | 134,136 | $15.83 | $2.1M | -79.9% | Form 4 ↗ |
| May 14, 2025 | NPCE Neuropace, Inc. | Sale | 34,000 | $15.94 | $542.0K | -79.9% | Form 4 ↗ |
| Apr 24, 2025 | PASG Passage Bio, Inc. | Sale | 68,195 | $0.32 | $21.8K | -72.6% | Form 4 ↗ |
| Apr 23, 2025 | PASG Passage Bio, Inc. | Sale | 89,328 | $0.34 | $30.4K | -77.6% | Form 4 ↗ |
| Apr 22, 2025 | PASG Passage Bio, Inc. | Sale | 78,049 | $0.34 | $26.5K | -82.4% | Form 4 ↗ |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Sale | 1,956 | $54.11 | $105.8K | +17.6% | Form 4 ↗ |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Sale | 3,026 | $54.11 | $163.7K | +17.6% | Form 4 ↗ |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Sale | 756 | $54.11 | $40.9K | +17.6% | Form 4 ↗ |
| Jan 14, 2025 | PASG Passage Bio, Inc. | Sale | 79,024 | $0.60 | $47.4K | -94.0% | Form 4 ↗ |
| Jan 13, 2025 | PASG Passage Bio, Inc. | Sale | 17,986 | $0.64 | $11.5K | -96.5% | Form 4 ↗ |
| Jan 10, 2025 | PASG Passage Bio, Inc. | Sale | 126,209 | $0.66 | $83.3K | -98.2% | Form 4 ↗ |
| Dec 11, 2024 | PASG Passage Bio, Inc. | Sale | 80 | $0.80 | $64 | -96.2% | Form 4 ↗ |
| Dec 10, 2024 | PASG Passage Bio, Inc. | Sale | 8,015 | $0.80 | $6,412 | -98.3% | Form 4 ↗ |
| Dec 9, 2024 | PASG Passage Bio, Inc. | Sale | 54,181 | $0.84 | $45.5K | -98.2% | Form 4 ↗ |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | Buy | 165,000 | $17.00 | $2.8M | -118.0% | Form 4 ↗ |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | Buy | 660,000 | $17.00 | $11.2M | -118.0% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.